Amyloidosis
Amyloidosis is a complex group of metabolic disorders in which misfolded proteins are deposited abnormally in the spaces between cells in tissues and organs. These abnormal proteins clump into microscopic fibrils with a highly stable beta-pleated sheet structure that resists breakdown by the body's own proteases. The deposits compress and destroy tissue and cause progressive organ dysfunction.
In dermatology and general medicine, amyloidosis falls into two distinct groups:
- Primary Cutaneous Amyloidosis (PCA): Amyloid fibrils, mostly derived from keratin released by damaged epidermal cells, are deposited only in the papillary dermis, with no internal organ involvement.
- Systemic Amyloidosis: Amyloid fibrils derived from circulating immunoglobulin light chains (AL), acute-phase protein (AA) or transthyretin (ATTR) are deposited in the heart, kidneys, liver, nerves and skin blood vessels.
At Haute-Derma, pinning down the exact type of amyloidosis with dermoscopy, a Congo red–stained biopsy and serum protein screening is essential. It allows us to rule out dangerous internal organ involvement and to build a treatment plan that repairs the skin barrier, relieves chronic itching and limits further amyloid build-up.
How Amyloid Forms and Its Tissue Characteristics
Staining, Fluorescence and Polarized Light Properties
The distinctive spatial arrangement of the beta-pleated sheets gives amyloid unique staining properties:
- Congo Red Staining: Amyloid stains brick red under an ordinary light microscope.
- Apple-Green Birefringence: Under polarized light, Congo red–stained tissue shows a characteristic apple-green birefringence. This is the gold standard for confirming amyloid.
- Thioflavin T/S Fluorescence: Amyloid fibrils bind strongly to thioflavin dyes and fluoresce under a fluorescence microscope.
Specialist Diagnosis at Haute-Derma
When a patient presents with rippled itchy papules or brown patches suggestive of amyloidosis, Haute-Derma follows a rigorous differential diagnosis process:
Dermoscopy
Dermoscopy at Haute-Derma reveals characteristic signs that separate amyloidosis from post-inflammatory hyperpigmentation (PIH) or lichen planus:
- Central White/Gray Hub: Corresponds to a dermal papilla filled with amyloid.
- Pigment Corona/Rays: Bands of melanin surround the central hub, giving a star-like or daisy-like pattern.
Skin Biopsy and Laboratory Screening
- Punch Biopsy: Samples the full thickness of the epidermis and papillary dermis. Congo red staining with polarized light microscopy outlines the amyloid fibrils.
- Ruling Out Internal Organ Involvement: For every diagnosis of nodular amyloidosis, or whenever there are signs of vascular bleeding, serum free light chains (kappa/lambda ratio) and immunofixation electrophoresis are mandatory.
Treatment and Comprehensive Management
Treating Primary Cutaneous Amyloidosis (PCA) at Haute-Derma
Primary cutaneous amyloidosis is not life-threatening, but its appearance and persistent itch can seriously affect quality of life. Our approach focuses on breaking the itch–scratch–amyloid deposition cycle:
Controlling Inflammation and Stubborn Itch
- Potent Topical Corticosteroids Under Occlusion: Clobetasol propionate 0.05% or betamethasone dipropionate is applied and covered with plastic film overnight (3–5 nights a week) to flatten thickened papules and calm inflammation.
- Calcineurin Inhibitors (Tacrolimus 0.1%): Used for maintenance, alternating after the steroid phase, to avoid skin thinning and keep local immunity stable.
- Oral Retinoids (Acitretin / Isotretinoin): For extensive lichen amyloidosis, to normalize epidermal keratinization and reduce abnormal keratin production.
Advanced Tissue-Remodeling Procedures at Haute-Derma
- Fractional CO2 Laser:
- The fractional CO2 laser creates tiny columns of thermal injury (microthermal zones, MTZs) that reach into the papillary dermis.
- How it works: The heat allows macrophages to move in and clear the accumulated amyloid deposits, while also stimulating new collagen.
- Q-Switched Nd:YAG / Picosecond Laser (1064 nm):
- Breaks up the dense melanin surrounding the amyloid deposits, treating the rippled dark patches of macular amyloidosis.
- Narrowband UVB Phototherapy (NB-UVB):
- Used for widespread itching that does not respond to topical treatment; it suppresses mast cells and sensory nerve endings in the dermis.
Treating Systemic Amyloidosis
Systemic amyloidosis requires coordinated care across several specialties (hematology, nephrology, cardiology):
- AL Type (Plasma Cell–Related):
- CyBorD regimen: cyclophosphamide + bortezomib (a proteasome inhibitor) + dexamethasone.
- Monoclonal antibody therapy: Daratumumab (an anti-CD38 antibody) achieves high hematologic response rates by eliminating the abnormal plasma cell clones.
- Autologous Stem Cell Transplant (ASCT): For younger patients whose heart and kidney function are still adequate.
- ATTR Type (Transthyretin-Related):
- Tafamidis: Binds to and stabilizes the transthyretin tetramer, preventing it from breaking apart into misfolded single chains.
- Patisiran / Inotersen: Small interfering RNA (siRNA) and antisense oligonucleotide drugs that silence the TTR gene in the liver, reducing production of the harmful TTR protein.
- AA Type (Related to Chronic Inflammation): Tight control of the underlying inflammatory disease with biologics (anti-TNF, tocilizumab – an anti-IL-6 agent) or colchicine (in familial Mediterranean fever).
